Based on the results of KEYNOTE-048 [5] and Checkmate-141 [29], the NCCN recommended the PD-1 inhibitor pembrolizumab or nivolumab to the R/M HNSCC alone or combination with chemotherapy. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.